Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
about
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches.Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapyExocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.Methods for 20S Immunoproteasome and 20S Constitutive Proteasome Determination Based on SPRI Biosensors.Construction of a recombinant lentivirus-mediated shRNA expression vector targeting the human PSMD10 gene and validation of RNAi efficiency in RPMI‑8226 multiple myeloma cells.The role of the proteasome in AML.Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.(Immuno)proteasomes as therapeutic target in acute leukemia.Positioning of proteasome inhibitors in therapy of solid malignancies.Immunoproteasome in the blood plasma of children with acute appendicitis, and its correlation with proteasome and UCHL1 measured by SPR imaging biosensors.Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch-Schönlein purpura and primary IgA nephropathy.Bortezomib for the treatment of acute lymphoblastic leukemia
P2860
Q33742779-9AF2085C-D06A-47CE-9B53-D893642DB6B1Q36293871-1B28498D-F15D-42F7-B43E-35F7F8F1C66DQ36544596-B8E5FA04-73F8-4F56-A505-47DD42D1F451Q37233146-BB643DE9-7238-49BE-9B4A-2ACCD98FF16FQ37688848-4549D23D-4B6D-4850-9BE4-97A96664619BQ37703203-BC626C9A-27DE-47A6-969E-7558541D3BADQ38698061-308C1F2C-1EA0-4B09-9562-01BC3F61E345Q39027087-FF544ED9-4974-42CE-A4B0-02CE9427D8A9Q39034873-DB9C55E4-DC00-4C82-8391-8A8BFD9FED6AQ41607725-9878D1AB-6D5D-406F-9DD3-D1F9BCAA4791Q47131929-E8771A3E-0B05-4875-96DF-D18A8526D058Q47353792-CB6EAB10-7E19-42C9-8B6A-B3893FE8D2CBQ47757096-2CB601F0-0776-4824-A7C2-FD202046F65CQ48322860-F0AB3613-25F1-4016-83FB-10F0ED176586Q57286691-56BCBC2F-6FD2-40CA-AFC8-2593372CEB1B
P2860
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Higher ratio immune versus con ...... ells to proteasome inhibitors.
@en
Higher ratio immune versus con ...... ells to proteasome inhibitors.
@nl
type
label
Higher ratio immune versus con ...... ells to proteasome inhibitors.
@en
Higher ratio immune versus con ...... ells to proteasome inhibitors.
@nl
prefLabel
Higher ratio immune versus con ...... ells to proteasome inhibitors.
@en
Higher ratio immune versus con ...... ells to proteasome inhibitors.
@nl
P2093
P2860
P1433
P1476
Higher ratio immune versus con ...... ells to proteasome inhibitors.
@en
P2093
Christopher J Kirk
Denise Niewerth
Gerrit Jansen
Gertjan J L Kaspers
Jacqueline Cloos
Janet Anderl
Jeremiah Degenhardt
Johan van Meerloo
Niels E Franke
Sonja Zweegman
P2860
P304
P356
10.3324/HAEMATOL.2013.092411
P577
2013-09-20T00:00:00Z